{"nctId":"NCT01181167","briefTitle":"A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty","startDateStruct":{"date":"2009-05"},"conditions":["Prevention","Venous Thromboembolism"],"count":610,"armGroups":[{"label":"DU-176b","type":"EXPERIMENTAL","interventionNames":["Drug: edoxaban"]},{"label":"enoxaparin sodium","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: enoxaparin sodium"]}],"interventions":[{"name":"edoxaban","otherNames":[]},{"name":"enoxaparin sodium","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients undergoing unilateral total hip arthroplasty\n\nExclusion Criteria:\n\n* Subjects with risks of hemorrhage\n* Subjects with thromboembolic risks\n* Subjects who weigh less than 40 kg\n* Subjects who are pregnant or suspect pregnancy, or subjects who want to become pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"84 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Subjects With Venous Thromboembolism Events","description":"The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment.\n\n* Lower extremity DVT confirmed by bilateral venography at the end of study treatment\n* Definite diagnosis of symptomatic PE\n* Symptomatic DVT confirmed before the venography at the end of study treatment The objectives were to verify the non-inferiority of edoxaban to enoxaparin with regard to prevention of VTE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"6.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Major Bleeding or Clinically Relevant Non-major Bleeding","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":303},"commonTop":["Alanine aminotransferase increased","Gamma-glutamyltransferase increased","Aspartate aminotransferase increased","Blood urine present","Blood alkaline phosphatase increased"]}}}